Atlantic Research Center LLC — research payments reported

By program year

6 rows

Year	Kind	Amount	Payments
2024	Research	$6,349	5
2023	Research	$6,349	5
2022	Research	$26,345	2
2021	Research	$199,246	14
2020	Research	$173,737	21
2019	Research	$116,695	44

Breakdown

Who paid Research payments · program years 2019–2024

Aimmune Therapeutics, Inc. $316,936 21 payments
Merck Sharp & Dohme Corporation $88,266 45 payments
Shire North American Group Inc $45,546 9 payments
Shionogi Inc $43,711 5 payments
VYNE Pharmaceuticals Inc. $21,565 1 payment
Sanofi US Services Inc. $12,698 10 payments

Studies the money was for Research payments · program years 2019–2024

Peanut Oral Immunotherapy Study of Early Intervention for Desensitization (Poseidon) $205,329 9 payments
A Multicenter, Open-Label, Long-Term Safety Study of AR101 Characterized Oral Desensitization Immunotherapy in Subjects Who Participated in A Prior Ar101 Study $95,877 8 payments
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 12-MonthStudy to Evaluate the Efficacy and Safety of MK-7264 in Adult Participants with ChronicCough PN030 $60,457 25 payments
Help Study Extensiontm An Open-Label Study to Evaluate the Long-Term Safety and Efficacy of Dx-2930 for Prevention Against Acute Attacks of Hereditary Angioedema Hae $45,546 9 payments
Evaluation of S-600918 in Adults With Refractory Chronic Cough $43,711 5 payments
Mti-117 $21,565 1 payment
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 12-Month Study to Evaluate the Efficacy and Safety of MK-7264 in Adult Participants with Chronic Cough PN030 $16,981 7 payments
Open-label, Interventional, Cohort Study to Evaluate Long-term Safety of Dupilumab in Patients With Moderate to Severe Asthma Who Completed the TRAVERSE-LTS12551 Clinical Trial $12,698 10 payments
Phase 2 Study of AR201 Oral Immunotherapy for Desensitization in Children, Adolescents, and Young Adults With Hen Egg Allergy $10,580 1 payment
A Phase III, Randomized, Placebo-Controlled Clinical Trial to Study the Efficacy and Safety of MK-3641, a Ragweed Ambrosia artemisiifolia Sublingual Immunotherapy Tablet, in Children With a History of Ragweed-Induced Rhinoconjunctivitis With or Without Asthma $8,387 4 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.